Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.
Cyclophosphamide is a cornerstone in the treatment of many pediatric and adult malignancies, as well as in the treatment of refractory autoimmune conditions. Genetic factors are thought to play a role in the interindividual variation in both response and toxicities associated with cyclophosphamide-based therapies. This drug focus reviews the most compelling studies conducted on the pharmacogenetics of cyclophosphamide-based therapies. Broader pharmacogenomic studies are needed and may reveal additional factors important in susceptibility to toxicity and/or response to therapy.
Pinto
Navin
N
University of Chicago, 900 East 57th Street, Room 7100, Chicago, IL 60637, USA.
Ludeman
Susan M
SM
Dolan
M Eileen
ME
D000444:Aldehyde Dehydrogenase / Q000235:genetics*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D005982:Glutathione Transferase / Q000235:genetics*; D006801:Humans; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
D003520:Cyclophosphamide; D003577:Cytochrome P-450 Enzyme System; D000444:Aldehyde Dehydrogenase; D005982:Glutathione Transferase